Skip to main content
. 2021 Dec 17;9(12):1931. doi: 10.3390/biomedicines9121931

Figure 4.

Figure 4

Plasma levels of CXCL10 were increased in PC patients according to the severity of the disease and to the presence of symptoms and signs of lung fibrosis. (A) Circulating CXCL10 levels were higher in severe PC patients who developed symptoms and signs of lung fibrosis compared to heathy and VAX subjects (blue dots vs. black and green dots). (B) CXCL10 levels were evaluated according to lung fibrosis-like symptoms. Data are expressed as median. Statistical analysis was performed according to the Mann–Whitney U test.